

X Original Supplemental Substitute

My residence, citizenship and mailing address are given below under my name.

PHARMACEUTICAL COMPOSITION WITH RESIDENCE AND CONTROLLED RELEASE

_____ is attached hereto.

<u>x</u> was filed on	<u>12 October 1999</u>	as PCT International
Application No.	<u>PCT/FR99/02443</u>	
and was amended on		(if applicable)

I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in Section 1.56 of Title 37 of the Code of Federal Regulations, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.

I hereby claim foreign priority benefit under Section 119 (a) - (d) of Title 35 of the United States Code of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States identified below and also identify below any foreign application(s) for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States filed by me on the same subject matter and having a filing date before that of the application(s) from which priority is claimed:

Page 1 of 3

I hereby claim benefit under Section 119(e) of Title 35 of the United States Code of any United States provisional application(s) identified below:

Application No. _____ Filing Date _____

I hereby claim benefit under Section 120 of Title 35 of the United States Code of any United States application(s) or PCT international application(s) designating the United States identified below:

Application Serial No. _____ Filing Date _____ Status _____

I hereby appoint Michael D. Alexander, Reg. No. 36,080; and Paul E. Dupont, Reg. No. 27,438, or any of them my attorneys or agents with full power of substitution and revocation to prosecute this application and to transact all business in the United States Patent and Trademark Office connected therewith.

SEND CORRESPONDENCE TO:

Patent Department
Sanofi-Synthelabo Inc.
9 Great Valley Parkway
P.O. Box 3026
Malvern, PA 19355

DIRECT TELEPHONE CALLS TO:

PAUL E. DUPONT

Telephone No. 610-889-6338

I hereby declare that all statements made herein and in the above-identified application of my/our own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of first joint inventor ALAUX Gérard
Inventor's signature _____ Date _____
Residence 33 rue du Roussillon, Val des Quatre Pignons – 78650 BEYNES – FRANCE
Citizenship French

Full name of second joint inventor ANDRE Frédéric
Inventor's signature _____ Date _____
Residence 14 bis rue du Clos de Massy – 92160 ANTONY – FRANCE
Citizenship French

Full name of third joint inventor CUINE Alain
Inventor's signature _____ Date _____
Residence 41 bis, allée de la Faisanderie – 77310 Saint Fargeau-Ponthierry - FRANCE
Citizenship French

Full name of fourth joint inventor LEWIS Gareth
Inventor's signature _____ Date _____
Residence 39 avenue de Paris – 91410 DOURDAN - FRANCE
Citizenship British